Functional studies of RYR1 mutations in the skeletal muscle ryanodine receptor using human RYR1 complementary DNA

Anesthesiology

Volumn 112, Issue 6, 2010, Pages 1350-1354

  Sato, Keisaku ^a   Pollock, Neil ^b   Stowell, Kathryn M ^a  

^a MASSEY UNIVERSITY   (New Zealand)

^b PALMERSTON NORTH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL; CALCIUM ION; CHLOROCRESOL; COMPLEMENTARY DNA; MAGNESIUM ION; RYANODINE RECEPTOR; RYANODINE RECEPTOR 1;

ARTICLE; CALCIUM TRANSPORT; CELL CULTURE; CELL STRAIN HEK293; CHANNEL GATING; CONTROLLED STUDY; DISEASE ASSOCIATION; EMBRYO; ENDOPLASMIC RETICULUM; EX VIVO STUDY; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MALIGNANT HYPERTHERMIA; MOLECULAR CLONING; MUSCLE CONTRACTION; MUSCLE METABOLISM; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; SARCOPLASMIC RETICULUM; SKELETAL MUSCLE;

EID: 77953019701     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3181d69283     Document Type: Article

References (25)

1. MacLennan DH, Duff C, Zorzato F, Fujii J, Phillips M, Korneluk RG, Frodis W, Britt BA, Worton RG: Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 1990; 343:559-561
2. McCarthy TV, Healy JM, Heffron JJ, Lehane M, Deufel T, Lehmann-Horn F, Farrall M, Johnson K: Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 1990; 343:562-564
3. Zhang Y, Chen HS, Khanna VK, De Leon S, Phillips MS, Schappert K, Britt BA, Browell AK, MacLennan DH: A mutation in the human ryanodine receptor gene associated with central core disease. Nat Genet 1993; 5:46-50
4. Denborough M, Lovell R: Anaesthetic deaths in a family. Lancet 1960; 2:45
5. Rosenberg H, Davis M, James D, Pollock N, Stowell K: Malignant hyperthermia. Orphanet J Rare Dis 2007; 2:21
6. Jungbluth H: Central core disease. Orphanet J Rare Dis 2007; 2:25
7. Carpenter D, Ismail A, Robinson RL, Ringrose C, Booms P, Iles DE, Halsall PJ, Steele D, Shaw MA, Hopkins PM: A RYR1 mutation associated with recessive congenital my-opathy and dominant malignant hyperthermia in Asian families. Muscle Nerve 2009; 40:633-639
8. Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P: Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat 2006; 27:977-989
9. Zullo A, Klingler W, De Sarno C, Ferrara M, Fortunato G, Perrotta G, Gravino E, Di Noto R, Lehmann-Horn F, Melzer W, Salvatore F, Carsana A: Functional characterization of ryanodine receptor (RYR1) sequence variants using a metabolic assay in immortalized B-lymphocytes. Hum Mutat 2009; 30:E575-90
10. von der Hagen M, Kress W, Hahn G, Brocke KS, Mitzscher-ling P, Huebner A, Muller-Reible C, Stoltenburg-Didinger G, Kaindl AM: Novel RYR1 missense mutation causes core rod myopathy. Eur J Neurol 2008; 15:e31-2
11. Tanabe T, Fukusaki M, Terao Y, Yamashita K, Sumikawa K, Mukaida K, Ibarra CA, Nishino I: Malignant hyperthermia susceptibility diagnosed with a family-specific ryanodine receptor gene type 1 mutation. J Anesth 2008; 22:70-73
12. Monnier N, Marty I, Faure J, Castiglioni C, Desnuelle C, Sacconi S, Estournet B, Ferreiro A, Romero N, Laquerriere A, Lazaro L, Martin JJ, Morava E, Rossi A, Van der Kooi A, de Visser M, Verschuuren C, Lunardi J: Null mutations causing depletion of the type 1 ryanodine receptor (RYR1) are commonly associated with recessive structural congenital myopathies with cores. Hum Mutat 2008; 29:670-678
13. Urwyler A, Deufel T, McCarthy T, West S: Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth 2001; 86:283-287
14. Anderson AA, Brown RL, Polster B, Pollock N, Stowell KM: Identification and biochemical characterization of a novel ryanodine receptor gene mutation associated with malignant hyperthermia. ANESTHESIOLOGY 2008; 108:208-215
15. Censier K, Urwyler A, Zorzato F, Treves S: Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia- susceptible and normal individuals. Effect of overexpression of recombinant wild-type and Arg163Cys mutated ryanodine receptors. J Clin Invest 1998; 101:1233-1242
16. Girard T, Cavagna D, Padovan E, Spagnoli G, Urwyler A, Zorzato F, Treves S: B-lymphocytes from malignant hyperthermia-susceptible patients have an increased sensitivity to skeletal muscle ryanodine receptor activators. J Biol Chem 2001; 276:48077-48082
17. Sei Y, Brandom BW, Bina S, Hosoi E, Gallagher KL, Wyre HW, Pudimat PA, Holman SJ, Venzon DJ, Daly JW, Mul-doon S: Patients with malignant hyperthermia demonstrate an altered calcium control mechanism in B lymphocytes. ANESTHESIOLOGY 2002; 97:1052-1058
18. Brown RL, Pollock AN, Couchman KG, Hodges M, Waaka R, Lynch P, McCarthy TV, Stowell KM: A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree. Hum Mol Genet 2000; 9:1515-1524
19. Miyazaki K, Takenouchi M: Creating random mutagenesis libraries using megaprimer PCR of whole plasmid. Biotech-niques 2002; 33:1033-4, 1036-1038
20. Du GG, Imredy JP, MacLennan DH: Characterization of recombinant rabbit cardiac and skeletal muscle Ca#sup#2+#/sup# release channels (ryanodine receptors) with a novel [#sup#3#/sup#H]ryanodine binding assay. J Biol Chem 1998; 273:33259-33266
21. Yang T, Ta TA, Pessah IN, Allen PD: Functional defects in six ryanodine receptor isoform-1 (RyR1) mutations associated with malignant hyperthermia and their impact on skeletal excitation-contraction coupling. J Biol Chem 2003; 278:25722-25730
22. Brini M, Manni S, Pierobon N, Du GG, Sharma P, MacLennan DH, Carafoli E: Ca#sup#2+#/sup# signaling in HEK-293 and skeletal muscle cells expressing recombinant ryanodine receptors harboring malignant hyperthermia and central core disease mutations. J Biol Chem 2005; 280:15380-15389
23. Tong J, McCarthy TV, MacLennan DH: Measurement of resting cytosolic Ca#sup#2+#/sup# concentrations and Ca#sup#2+#/sup# store size in HEK-293 cells transfected with malignant hyperthermia or central core disease mutant Ca#sup#2+#/sup# release channels. J Biol Chem 1999; 274:693-702
24. Dirksen RT, Avila G: Distinct effects on Ca#sup#2+#/sup# handling caused by malignant hyperthermia and central core disease mutations in RyR1. Biophys J 2004; 87:3193-3204
25. Tilgen N, Zorzato F, Halliger-Keller B, Muntoni F, Sewry C, Palmucci LM, Schneider C, Hauser E, Lehmann-Horn F, Muller CR, Treves S: Identification of four novel mutations in the C-terminal membrane spanning domain of the ryanodine receptor 1: Association with central core disease and alteration of calcium homeostasis. Hum Mol Genet 2001; 10:2879-2887